AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10216905 — intervention group
Group type: EXPERIMENTAL
Intervention: Filtered units
Number of subjects: 72
Study 10216905 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma units
Number of subjects: 72
Study 10216905 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold hold units
Number of subjects: 72
Study 10216905 — intervention group
Group type: COMPARATOR
Intervention: Plasma storage parameters
Number of subjects: 72
Study 7781725 — intervention group
Group type: EXPERIMENTAL
Intervention: Static magnetic field exposure from bonded samarium-cobalt magnets (100-150 Gauss for dental pulp, 200-900 Gauss for gingival tissues)
Number of subjects: 7
Study 7781725 — intervention group
Group type: COMPARATOR
Intervention: Demagnetized magnet (control)
Number of subjects: 7
Study 2077596 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine 4 degrees C
Number of subjects: 66
Study 2077596 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine 20 degrees C
Number of subjects: 66
Study 2077596 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine 37 degrees C
Number of subjects: 66
Study 2077596 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural injection of saline at 37 degrees C
Number of subjects: 66
Study 2077596 — intervention group
Group type: COMPARATOR
Intervention: Self-limited tremor
Number of subjects: 66
Study 231324 — intervention group
Group type: EXPERIMENTAL
Intervention: Phanurane (2 gelules daily, 2 X 50 mg of canrenone)
Number of subjects: 61
Study 231324 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study 29510613 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 56
Study 28192854 — intervention group
Group type: EXPERIMENTAL
Intervention: TRP agonist
Number of subjects: 39
Study 28192854 — intervention group
Group type: COMPARATOR
Intervention: Vehicle control
Number of subjects: 39
Study 25734870 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenting group intervention (N=34)
Number of subjects: 80
Study 25734870 — intervention group
Group type: COMPARATOR
Intervention: Health focused control group (N=46)
Number of subjects: 80
Study 23621350 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 μg rBet v 1‐FV
Number of subjects: 37
Study 23621350 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 μg rBet v 1‐FV
Number of subjects: 37
Study 23621350 — intervention group
Group type: EXPERIMENTAL
Intervention: 160 μg rBet v 1‐FV
Number of subjects: 37
Study 23621350 — intervention group
Group type: EXPERIMENTAL
Intervention: 320 μg rBet v 1‐FV
Number of subjects: 37
Study 23621350 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study 22185606 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual hypnotherapy (6 sessions)
Number of subjects: 354
Study 22185606 — intervention group
Group type: EXPERIMENTAL
Intervention: Group hypnotherapy (6 sessions)
Number of subjects: 354
Study 22185606 — intervention group
Group type: COMPARATOR
Intervention: Educational supportive therapy in a group (placebo, 6 sessions)
Number of subjects: 354
Study 22185606 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual hypnotherapy
Number of subjects: 354
Study 22185606 — intervention group
Group type: EXPERIMENTAL
Intervention: Group hypnotherapy
Number of subjects: 354
Study 22185606 — intervention group
Group type: COMPARATOR
Intervention: Educational supportive therapy in a group (placebo)
Number of subjects: 354
Study 19422286 — intervention group
Group type: EXPERIMENTAL
Intervention: BEMER magnetic field treatment for 8 minutes twice daily for 12 weeks
Number of subjects: 37
Study 19422286 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment for 12 weeks
Number of subjects: 37
Study 16769944 — intervention group
Group type: EXPERIMENTAL
Intervention: Andersen-Tawil syndrome (ATS) subjects
Number of subjects: 20
Study 15019375 — intervention group
Group type: EXPERIMENTAL
Intervention: Latanoprost 0.005% and timolol 0.5% once daily
Number of subjects: 253
Study 15019375 — intervention group
Group type: COMPARATOR
Intervention: Dorzolamide 2% and timolol 0.5% twice daily
Number of subjects: 253
Study 11393598 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavior therapy (CBT)
Number of subjects: 76
Study 11393598 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure and response prevention (ERP)
Number of subjects: 76
Study 11393598 — intervention group
Group type: COMPARATOR
Intervention: Control condition (wait-list)
Number of subjects: 76
Study 9251276 — intervention group
Group type: EXPERIMENTAL
Intervention: Exchange transfusion (ET)
Number of subjects: 40
Study 9251276 — intervention group
Group type: COMPARATOR
Intervention: No exchange transfusion (controls)
Number of subjects: 40
Study 8281566 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional bite-wing radiography
Number of subjects: 168
Study 8281566 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital bite-wing radiography
Number of subjects: 168
Study 8281566 — intervention group
Group type: COMPARATOR
Intervention: Clinical examination alone
Number of subjects: 168
Study 3493333 — intervention group
Group type: EXPERIMENTAL
Intervention: PAG-PVG stimulation
Number of subjects: 45
Study 3493333 — intervention group
Group type: COMPARATOR
Intervention: Thalamic sensory relay nuclei stimulation
Number of subjects: 45
Study 3493333 — intervention group
Group type: COMPARATOR
Intervention: Morphine sulfate (blind, placebo-controlled protocol)
Number of subjects: 45
Study 3493333 — intervention group
Group type: COMPARATOR
Intervention: Intravenous naloxone (double-blind, placebo-controlled protocol)
Number of subjects: 45
Study 29979640 — intervention group
Group type: EXPERIMENTAL
Intervention: LGBT women veterans
Number of subjects: 1391
Study 29979640 — intervention group
Group type: COMPARATOR
Intervention: Non-LGBT women veterans
Number of subjects: 1391
Study 28807006 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy Lifestyles Programme (HeLP) - an obesity prevention programme
Number of subjects: 1324
Study 26584951 — intervention group
Group type: EXPERIMENTAL
Intervention: Levodopa/carbidopa 100/25 mg TID for 40 weeks (including 2 weeks of dose escalation)
Number of subjects: 446
Study 26584951 — intervention group
Group type: COMPARATOR
Intervention: Placebo TID for 40 weeks
Number of subjects: 446
Study 26584951 — intervention group
Group type: EXPERIMENTAL
Intervention: Levodopa/carbidopa 100/25 mg TID for 40 weeks (after initial 40 weeks of treatment)
Number of subjects: 446
Study 23180405 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferrous ascorbate
Number of subjects: 73
Study 23180405 — intervention group
Group type: COMPARATOR
Intervention: Colloidal iron
Number of subjects: 73
Study 22035675 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher resting systolic BP levels in girls
Number of subjects: 235
Study 22035675 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher resting diastolic BP levels in young girls (8-11 years)
Number of subjects: 235
Study 22035675 — intervention group
Group type: COMPARATOR
Intervention: Age
Number of subjects: 235
Study 18779882 — intervention group
Group type: EXPERIMENTAL
Intervention: Dysport 200 U/ml
Number of subjects: 36
Study 18779882 — intervention group
Group type: EXPERIMENTAL
Intervention: Dysport 150 U/ml
Number of subjects: 36
Study 18779882 — intervention group
Group type: EXPERIMENTAL
Intervention: Dysport 100 U/ml
Number of subjects: 36
Study 18779882 — intervention group
Group type: COMPARATOR
Intervention: Botox 100 U/ml
Number of subjects: 36
Study 16554494 — intervention group
Group type: EXPERIMENTAL
Intervention: Homozygous carriers of the G-allele
Number of subjects: 226
Study 16554494 — intervention group
Group type: COMPARATOR
Intervention: Controls (non-carriers)
Number of subjects: 226
Study 12942590 — intervention group
Group type: EXPERIMENTAL
Intervention: Sinemet
Number of subjects: 30
Study 12942590 — intervention group
Group type: COMPARATOR
Intervention: Grifoparkin
Number of subjects: 30
Study 10690944 — intervention group
Group type: EXPERIMENTAL
Intervention: Half dose epinephrine (0.375 microg/min)
Number of subjects: 10
Study 10690944 — intervention group
Group type: EXPERIMENTAL
Intervention: Full dose epinephrine (0.75 microg/min)
Number of subjects: 10
Study 10690944 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 10
Study 10690944 — intervention group
Group type: EXPERIMENTAL
Intervention: Epinephrine studies (both doses)
Number of subjects: 10
Study 9513252 — intervention group
Group type: EXPERIMENTAL
Intervention: Albumin-impregnated prostheses
Number of subjects: 100
Study 9513252 — intervention group
Group type: COMPARATOR
Intervention: Non-impregnated polyester knitted vascular prostheses
Number of subjects: 100
Study 8191053 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen therapy with Naftidrofuryl, 1 session per day
Number of subjects: 0
Study 8191053 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen therapy with Naftidrofuryl, 2 sessions per day
Number of subjects: 0
Study 2873094 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatostatin
Number of subjects: 56
Study 2873094 — intervention group
Group type: COMPARATOR
Intervention: Cimetidine
Number of subjects: 56
Study 30362133 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured peer‐assisted learning program using deliberate practice (Group A, n=15)
Number of subjects: 43
Study 30362133 — intervention group
Group type: COMPARATOR
Intervention: Unstructured peer‐supported environment (Group B, n=15)
Number of subjects: 43
Study 30362133 — intervention group
Group type: COMPARATOR
Intervention: Assessment‐only control group (Group C, n=13)
Number of subjects: 43
Study 28339745 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic nasal Staphylococcus aureus carriage (CNSAC)
Number of subjects: 200
Study 28339745 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic nasal Staphylococcus aureus carriage (CNSAC) in generalized GPA
Number of subjects: 200
Study 28339745 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic nasal Staphylococcus aureus carriage (CNSAC) in early systemic GPA during immunosuppression
Number of subjects: 200
Study 28339745 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic trimethoprim/sulfamethoxazole (T/S)
Number of subjects: 200
Study 26027612 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporine (2.5 mg/kg intravenous infusion)
Number of subjects: 975
Study 26027612 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 975
Study 23215966 — intervention group
Group type: EXPERIMENTAL
Intervention: Short treatment (three x two-hour sessions)
Number of subjects: 20
Study 23215966 — intervention group
Group type: COMPARATOR
Intervention: Waitlist (control group)
Number of subjects: 20
Study 21415156 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin at baseline
Number of subjects: 100
Study 21415156 — intervention group
Group type: COMPARATOR
Intervention: No aspirin at baseline
Number of subjects: 100
Study 19722788 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate-restoration group (n = 30)
Number of subjects: 60
Study 19722788 — intervention group
Group type: COMPARATOR
Intervention: One-stage group (n = 30)
Number of subjects: 60
Study 17321312 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stents (SES)
Number of subjects: 8146
Study 17321312 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel-eluting stents (PES)
Number of subjects: 8146
Study 17321312 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual antiplatelet therapy
Number of subjects: 8146
Study 15475125 — intervention group
Group type: EXPERIMENTAL
Intervention: Powered wheelchair manoeuvres
Number of subjects: 10
Study 15475125 — intervention group
Group type: EXPERIMENTAL
Intervention: Forward steering
Number of subjects: 10
Study 15475125 — intervention group
Group type: EXPERIMENTAL
Intervention: Backwards steering
Number of subjects: 10
Study 15475125 — intervention group
Group type: EXPERIMENTAL
Intervention: Left steering
Number of subjects: 10
Study 15475125 — intervention group
Group type: EXPERIMENTAL
Intervention: Right steering
Number of subjects: 10
Study 15475125 — intervention group
Group type: EXPERIMENTAL
Intervention: JASA analysis
Number of subjects: 10
Study 11504589 — intervention group
Group type: EXPERIMENTAL
Intervention: Respiratory muscle training (RMT)
Number of subjects: 9
Study 11504589 — intervention group
Group type: COMPARATOR
Intervention: Placebo (sham hypoxic trainer)
Number of subjects: 9
Study 9659472 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional tape
Number of subjects: 50
Study 9659472 — intervention group
Group type: COMPARATOR
Intervention: Plaster cast
Number of subjects: 50
Study 7645637 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg of aspirin
Number of subjects: 606
Study 2524684 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyproterone acetate 27 mg plus ethinyl estradiol 0.035 mg/day
Number of subjects: 23
Study 2524684 — intervention group
Group type: COMPARATOR
Intervention: Danazol 600 mg/day
Number of subjects: 23
Study 22216503 — intervention group
Group type: EXPERIMENTAL
Intervention: Frusemide (40 mg)
Number of subjects: 10
Study 22216503 — intervention group
Group type: EXPERIMENTAL
Intervention: Bumetanide (1 mg)
Number of subjects: 10
Study 30957449 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupoint catgut embedding
Number of subjects: 100
Study 30957449 — intervention group
Group type: COMPARATOR
Intervention: Bupropion hydrochloride sustained-release tablets
Number of subjects: 100
Study 29079252 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive therapy (HbA1c <6.2% [44.3 mmol/mol], blood pressure <120/75 mm Hg, LDL cholesterol <80 mg/dL [or 70 mg/dL in patients with a history of coronary artery disease])
Number of subjects: 2542
Study 29079252 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy (targets: HbA1c <6.9% [52.0 mmol/mol], blood pressure <130/80 mm Hg, LDL cholesterol <120 mg/dL [or 100 mg/dL in patients with a history of coronary artery disease])
Number of subjects: 2542
Study 25971655 — intervention group
Group type: COMPARATOR
Intervention: Pre-operative education
Number of subjects: 209
Study 25971655 — intervention group
Group type: COMPARATOR
Intervention: Mini-invasive surgery
Number of subjects: 209
Study 23239680 — intervention group
Group type: EXPERIMENTAL
Intervention: Milk supplementation (24 oz/day, one 16-oz dose immediately post-RT)
Number of subjects: 108
Study 23239680 — intervention group
Group type: EXPERIMENTAL
Intervention: Isocaloric carbohydrate (100% fruit juice)
Number of subjects: 108
Study 23239680 — intervention group
Group type: COMPARATOR
Intervention: Water (control)
Number of subjects: 108
Study 21184185 — intervention group
Group type: EXPERIMENTAL
Intervention: Mometasone furoate/formoterol fumarate (MF/F) combination
Number of subjects: 1518
Study 21184185 — intervention group
Group type: COMPARATOR
Intervention: Formoterol fumarate (F)
Number of subjects: 1518
Study 21184185 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1518
Study 19028124 — intervention group
Group type: EXPERIMENTAL
Intervention: Teriparatide (20 microg/d)
Number of subjects: 428
Study 19028124 — intervention group
Group type: COMPARATOR
Intervention: Alendronate (10 mg/d)
Number of subjects: 428
Study 17270315 — intervention group
Group type: EXPERIMENTAL
Intervention: Eflornithine cream plus laser treatment
Number of subjects: 31
Study 17270315 — intervention group
Group type: COMPARATOR
Intervention: Laser treatment alone (placebo cream)
Number of subjects: 31
Study 15050263 — intervention group
Group type: EXPERIMENTAL
Intervention: LASEK with a larger (6.5 mm) zone with 8.0 mm blend zone
Number of subjects: 19
Study 15050263 — intervention group
Group type: COMPARATOR
Intervention: LASEK with a conventional (6.0 mm) optical zone
Number of subjects: 19
Study 11699049 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress hormone infusion
Number of subjects: 16
Study 9140509 — intervention group
Group type: EXPERIMENTAL
Intervention: Insecticide-treated bed nets (ITBN)
Number of subjects: 1479
Study 9140509 — intervention group
Group type: COMPARATOR
Intervention: Control group (no ITBN)
Number of subjects: 1479
Study 7950114 — intervention group
Group type: EXPERIMENTAL
Intervention: True Vista bifocal lens (group I)
Number of subjects: 34
Study 7950114 — intervention group
Group type: COMPARATOR
Intervention: Accurasee bifocal lens (group II)
Number of subjects: 34
Study 3165436 — intervention group
Group type: EXPERIMENTAL
Intervention: Levodopa sustained-release (S. R.) formulations
Number of subjects: 2
Study 3165436 — intervention group
Group type: COMPARATOR
Intervention: Standard preparation of levodopa
Number of subjects: 2
Study 31148332 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin
Number of subjects: 64
Study 31148332 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin
Number of subjects: 64
Study 28587581 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg enalapril (E) for 4 weeks
Number of subjects: 34
Study 28587581 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg enalapril (E) with or without hydrochlorothiazide (acute treatment)
Number of subjects: 34
Study 28587581 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg enalapril (E) + 16 mg candesartan (EC) for chronic treatment
Number of subjects: 34
Study 28587581 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher plasma ACE concentration
Number of subjects: 34
Study 25246074 — intervention group
Group type: EXPERIMENTAL
Intervention: HA viscosupplementation (3 weekly intra-articular injections of HA)
Number of subjects: 86
Study 25246074 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 86
Study 24168767 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequent exacerbators (≥ 2 exacerbations during study treatment)
Number of subjects: 7376
Study 24168767 — intervention group
Group type: EXPERIMENTAL
Intervention: Exacerbation-related hospitalisations
Number of subjects: 7376
Study 21839994 — intervention group
Group type: EXPERIMENTAL
Intervention: Circumferential radiofrequency ablation (RFA)
Number of subjects: 29
Study 18430744 — intervention group
Group type: EXPERIMENTAL
Intervention: Lornoxicam (0.1 mg kg(‐1))
Number of subjects: 22
Study 18430744 — intervention group
Group type: COMPARATOR
Intervention: Saline (control group)
Number of subjects: 22
Study 17161233 — intervention group
Group type: EXPERIMENTAL
Intervention: Inslow (palatinose-based liquid diet)
Number of subjects: 7
Study 15243316 — intervention group
Group type: EXPERIMENTAL
Intervention: Eductyl
Number of subjects: 20
Study 15243316 — intervention group
Group type: EXPERIMENTAL
Intervention: Eductyl + psyllium
Number of subjects: 20
Study 15243316 — intervention group
Group type: COMPARATOR
Intervention: Psyllium
Number of subjects: 20
Study 11317154 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplemented Group (A) with SUPRO Isolated Soy Protein (1 g/kg body weight)
Number of subjects: 14
Study 11317154 — intervention group
Group type: COMPARATOR
Intervention: Non‐Supplemented Group (B) with placebo
Number of subjects: 14
Study 9389278 — intervention group
Group type: EXPERIMENTAL
Intervention: Pethidine 25 mg
Number of subjects: 90
Study 9389278 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil 250 micrograms
Number of subjects: 90
Study 9389278 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (placebo)
Number of subjects: 90
Study 7696152 — intervention group
Group type: EXPERIMENTAL
Intervention: CYTOPRESS semi‐automatic slide preparation system and CERVIFIP interactive scanner
Number of subjects: 701
Study 3311924 — intervention group
Group type: EXPERIMENTAL
Intervention: cis‐platinum and cyclophosphamide
Number of subjects: 267
Study 3311924 — intervention group
Group type: COMPARATOR
Intervention: cis‐platinum, cyclophosphamide, and doxorubicin
Number of subjects: 267
Study 30309755 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold tumescence anesthesia solution (4°C)
Number of subjects: 51
Study 30309755 — intervention group
Group type: COMPARATOR
Intervention: Room temperature tumescence anesthesia solution (24°C)
Number of subjects: 51
Study 28068978 — intervention group
Group type: EXPERIMENTAL
Intervention: YourCall™ text message intervention (16 informational and motivational text messages delivered over 4 weeks)
Number of subjects: 0
Study 28068978 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 0
Study 28068978 — intervention group
Group type: EXPERIMENTAL
Intervention: YourCall™ text message intervention
Number of subjects: 0
Study 27097858 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnosis prior to local anesthesia administration
Number of subjects: 200
Study 27097858 — intervention group
Group type: COMPARATOR
Intervention: Control group (no hypnosis)
Number of subjects: 200
Study 24366425 — intervention group
Group type: EXPERIMENTAL
Intervention: High molecular weight (HMW) urinary adiponectin excretion
Number of subjects: 141
Study 24366425 — intervention group
Group type: EXPERIMENTAL
Intervention: HMW-adiponectin excretion
Number of subjects: 141
Study 24366425 — intervention group
Group type: EXPERIMENTAL
Intervention: HMW-adiponectin
Number of subjects: 141
Study 24366425 — intervention group
Group type: COMPARATOR
Intervention: Total adiponectin excretion
Number of subjects: 141
Study 24366425 — intervention group
Group type: COMPARATOR
Intervention: Albumin excretion rate (AER)
Number of subjects: 141
Study 22761709 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem sustained-release capsules (90 mg twice daily)
Number of subjects: 80
Study 22761709 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 22761709 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem sustained-release capsules
Number of subjects: 80
Study 22761709 — intervention group
Group type: COMPARATOR
Intervention: Diltiazem sustained-release capsules and Placebo
Number of subjects: 80
Study 19390588 — intervention group
Group type: EXPERIMENTAL
Intervention: Fatty fish (n = 11)
Number of subjects: 33
Study 19390588 — intervention group
Group type: EXPERIMENTAL
Intervention: Lean fish (n = 12)
Number of subjects: 33
Study 19390588 — intervention group
Group type: COMPARATOR
Intervention: Control (n = 10)
Number of subjects: 33
Study 17702957 — intervention group
Group type: EXPERIMENTAL
Intervention: Treadmill aerobic training (T‐AEX)
Number of subjects: 46
Study 17702957 — intervention group
Group type: COMPARATOR
Intervention: Attention-matched stretching intervention (CONTROL)
Number of subjects: 46
Study 15071378 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical emergency team intervention
Number of subjects: 2183
Study 11845949 — intervention group
Group type: EXPERIMENTAL
Intervention: Adapalene gel 0.1%
Number of subjects: 150
Study 11845949 — intervention group
Group type: COMPARATOR
Intervention: Tretinoin gel 0.025%
Number of subjects: 150
Study 9751346 — intervention group
Group type: EXPERIMENTAL
Intervention: Transurethral alprostadil
Number of subjects: 384